Comparison of Drug Utilization Patterns in Observational Data: Antiepileptic Drugs in Pediatric Patients by Bourgeois, Florence Tanya et al.
Comparison of Drug Utilization
Patterns in Observational Data:
Antiepileptic Drugs in Pediatric Patients
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Bourgeois, Florence T., Karen L. Olson, Annapurna Poduri,
and Kenneth D. Mandl. 2015. “Comparison of Drug Utilization
Patterns in Observational Data: Antiepileptic Drugs in Pediatric
Patients.” Pediatric Drugs 17 (5) (June 13): 401–410. doi:10.1007/
s40272-015-0139-z.
Published Version 10.1007/s40272-015-0139-z
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:33749492
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Open Access Policy Articles, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#OAP
Comparison of drug utilization patterns in observational data: 
antiepileptic drugs in pediatric patients
Florence T Bourgeois, MD, MPH1,2,3, Karen L Olson, PhD1,2,3, Annapurna Poduri, MD2,4, 
and Kenneth D Mandl, MD, MPH1,2,3
1Division of Emergency Medicine, Boston Children’s Hospital, Boston, MA, U.S.A.
2Department of Pediatrics, Harvard Medical School, Boston, MA, U.S.A.
3Children’s Hospital Informatics Program, Boston Children’s Hospital, Boston, MA, U.S.A.
4Department of Neurology, Harvard Medical School, Boston, MA, U.S.A.
Abstract
Purpose—Physicians require information on the comparative benefits and harms of medications 
for optimal treatment decisions. However, this type of data is limited, especially for pediatric 
patients.
Objective—Our aim was to use observational data to measure and compare medication 
utilization patterns in a pediatric patient population.
Methods—Using pharmacy claims data from a large, national-scale insurance program in the 
US, we identified all patients with a diagnosis of epilepsy treated with a first-generation 
(carabamazepine, ethosuximide, phenobarbital, phenytoin, valproate) or second-generation 
(carbamazepine XR, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, 
valproate XR, zonisamide) antiepileptic drug. Treatment periods were defined based on 
prescription fill dates and medication days supplied. Medication use was measured for individual 
antiepileptic drugs and for first-generation and second-generation drugs as groups.
Results—There were 2527 (54%) patients who initiated therapy with first-generation and 2139 
(46%) with second-generation antiepileptics. First- and second-generation drugs had the same 
one-year retention rates (26% [95%CI 24–28] and 26% [95%CI 25–28], respectively). A total of 
26% (95%CI 25–28) and 29% (95%CI 27–31) of patients who started on a first- or second-
generation antiepileptic medication, respectively, resumed treatment with the initial drug after 
discontinuation. Overall, 73% (95%CI 71–74) of patients were treated with only one antiepileptic 
drug, with similar rates for patients started on first- and second-generation drugs (71% [95%CI 
69–73] vs 74% [95%CI 72–76]).
Conclusions—Comparing drug utilization patterns in a pediatric population using observational 
data, we found similar rates of retention and therapeutic changes. These findings are consistent 
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with available comparative data and demonstrate an approach that could be extended to other drug 
classes and conditions in pediatric populations to examine drug effectiveness.
INTRODUCTION
Physicians frequently lack comparative data when choosing from the growing 
armamentarium of pharmaceuticals and, as a result, there is tremendous variation in 
treatment practice.1,2 The lack of comparative effectiveness data is particularly pronounced 
for pediatric patients, given the small number of drug trials conducted in children compared 
with adults.3–7 Clinicians often show a preference for newer drugs, but not infrequently, 
newer drugs are later found to be less effective or safe than previously existing options.8–10 
New drugs are generally approved based on demonstrated superiority to placebo and 
regulatory agencies—including the Food and Drug Administration (FDA) in the United 
States—typically do not require comparison to existing agents.1,11–13 If there were 
information available to clinicians and patients on the advantages and disadvantages of a 
medication compared to others in the same class, they might be less likely to opt for the 
newer and more costly agent and better able to select the drug that would yield the greatest 
health benefits for a specific patient.
There are many barriers to conducting large, randomized controlled drug trials in children 
and sole reliance on these trials to increase comparative drug data in this population may not 
be feasible. Therefore, we sought to leverage observational data to compare drug 
effectiveness based on drug utilization patterns, focusing here on first- and second-
generation antiepileptic drugs in a pediatric patient population. For example, the length of 
time a patient continues therapy with a specific medicine may be reflective of the drug’s 
efficacy as well as safety and tolerability and these measures can be gleaned from 
prescription fill patterns in health insurance claims data.
Between 1994 and 2009, 10 new antiepileptic agents were approved by the FDA and readily 
adopted by many clinicians.14 However, there is limited data available describing how these 
newer, or second-generation, drugs compare to the older, first-generation agents.15 
Observational data on drug utilization may provide the opportunity to compare the 
effectiveness of different treatment options in large patient populations over extended 
periods and augment data generated in controlled trials. The aim of this study was to use 
observational data to measure and compare medication utilization in a pediatric patient 
population treated with antiepileptic drugs.
METHODS
Data Source and Patient Population
The study population was 1,604,580 children between 0 and 18 years of age enrolled in a 
private national-scale insurance program in the United States. Members enrolled in this plan 
shared a common employer, were located throughout the United States, and were fully 
insured. Insurance claims for the program were available from January 1, 1999 through 
December 31, 2006 and included demographic data, information on medical encounters, and 
pharmacy prescription claims data. Prescription data consisted of National Drug Codes, date 
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of prescription fill, and number of days supplied. Data on specific dosing regimens was not 
available. All patient information were de-identified. The Committee on Clinical 
Investigation at Boston Children’s Hospital deemed that the study did not represent human 
subjects research and granted a waiver of informed consent.
Patients were included in the study if they were enrolled in the insurance program for at 
least 120 days without filling a prescription for an antiepileptic drug, had at least one 
medical encounter associated with a diagnosis of epilepsy or seizures (as defined in the 
International Classification of Diseases, Ninth Review, codes 345.xx, 779.0, 780.3x), 
initiated antiepileptic therapy with a single antiepileptic medication.16–18 We considered 
diagnoses associated with both outpatient and inpatient visits. For patients treated with a 
specific antiepileptic drug for 30 days or less with no subsequent prescriptions for the same 
drug within 12 months of the initial treatment, we used the second antiepileptic drug 
(whenever a second one was prescribed) as the index drug for analysis. This was done in 
order to avoid analyzing drug utilization for medications used on a temporary basis, for 
example while the definitive medication is being titrated to the full dose. However, since 
this may also lead to the exclusion of patients who discontinue treatment due to safety or 
efficacy concerns within the first 30 days of treatment, we performed a sensitivity analysis 
in which patients treated with a medication for 30 days or less were included. The results 
were very similar to those of the main analysis in terms of comparative utilization patterns 
between first- and second-generation medications (Appendix Tables 1 and 2). Patients with 
less than a year of continuous insurance coverage after initiation of the index drug were 
dropped from further analysis.
Definition of Antiepileptic Drugs
Antiepileptic drugs were identified based on the Multum Drug Classification and included 
all medications listed in the category “anticonvulsants”.19 We excluded acetazolamide, 
magnesium sulfate, clonazepam, diazepam, and lorazepam for the purposes of this study 
since these are not considered primarily anticonvulsant agents. Ethotoin was also excluded 
because no patient in the study cohort was treated with this agent. First-generation drugs 
were those approved by the FDA pre-1993 and second-generation drugs those approved 
post-1993.20
Definition of Medication Treatment Periods
Medication treatment periods were defined as beginning on the day a prescription was filled 
and extending for the total number of medication days supplied. Gaps in medication 
treatment were defined as the total number of continuous days without medication supply.16 
Gaps between prescriptions lasting 30 days or less were considered the result of poor 
medication adherence and the period analyzed as a continuous treatment period.16,21–23 This 
was done for consecutive prescriptions for the same drug as well as consecutive 
prescriptions for different antiepileptic agents. In these cases, the start date of the second 
prescription was considered the end date of the first prescription. Treatment gaps of 31 days 
or greater were defined as separate treatment periods.
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Similarly, overlaps in treatment periods were not considered periods of combination therapy 
if they lasted 30 days or less. The treatment end date for the first drug was defined as the 
date the second agent was started. This was done for consecutive prescriptions of the same 
agent as well as for consecutive prescriptions of different antiepileptic drugs. Periods of 
combination drug treatment were defined as periods lasting longer than 30 days during 
which the subject was treated with more than one antiepileptic medication.
Drug Comparisons
We compared medication usage focusing on medication retention (the continuation of 
treatment after medication start) and therapeutic changes during the first year following 
treatment initiation. We examined 5 measures of medication retention: 1) Continuous 
treatment: days of continuous treatment with the index drug before any change in the 
antiepileptic drug regimen (including the discontinuation of the index drug or the addition of 
one or more antiepileptic drugs); 2) Continuous treatment including polytherapy: days of 
continuous treatment with the index drug including days of treatment with one or more other 
antiepileptic drugs; 3) Proportion treatment days with index drug: proportion of total 
treatment days over the course of the study period during which patients are treated with the 
index drug; 4) One-year retention: rate of index drug retention one year after initiation 
without any gaps in treatment or addition of other drugs; and 5) Treatment resumption: 
Proportion of patients who resume treatment with the index drug after it has been 
discontinued.
Four measures describe patterns of therapeutic changes following treatment initiation: 1) 
Proportion monotherapy: The proportion of patients treated with only the index drug 
throughout the study period; 2) Proportion polytherapy: the proportion of patients who 
require the addition of a second antiepileptic drug concurrent with the index drug during the 
first treatment period; 3) Number of antiepileptic drugs: the total number of anticonvulsants 
prescribed throughout the study period; and 4) Number of therapeutic adjustments: the 
number of changes in treatment regimen (including discontinuing, adding, and restarting an 
antiepileptic drug) throughout the study period.
Statistical Analysis
Medication use was measured for individual antiepileptic drugs and for first-generation and 
second-generation drugs as groups. Means and proportions were calculated with 95% 
confidence intervals (CI). Kaplan-Meier survival analyses were used to calculate retention 
rates at one year and log-rank tests performed to compare the retention curves. Post-hoc 
analyses used the Sidak adjustment for multiple comparisons. All data were analyzed with 
SAS statistical software (version 9.3, SAS Institute Inc., Cary, North Carolina).24
RESULTS
Study Population
We identified 10,083 patients 0 to 18 years of age who had a medical encounter associated 
with the diagnosis of epilepsy or seizure and were treated with an antiepileptic agent. Of 
these, 6,033 had a 120-day period without prescriptions for an antiepileptic drug and 6,158 
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initiated treatment with a single agent. Of these, 879 patients were excluded because they 
were not continuously enrolled for one year after the initiation of the index drug. Another 
478 patients were excluded because they were treated with an antiepileptic drug for 30 days 
or less without a second antiepileptic drug prescription. Five of the 19 antiepileptic drugs 
identified in the dataset were dropped because few patients initiated treatment with them 
(felbamate N=2, mephobarbital N=2, methsuximide N=1, pregabalin N=1, and primidone 
N=4). The final study cohort consisted of 4666 patients.
There were 2527 (54%) patients in our study sample who initiated therapy with first-
generation antiepileptic drugs and 2139 (46%) with second-generation drugs. Characteristics 
of patients initiated on first- and second-generation drugs were slightly different with 
patients initiating first-generation drugs slightly younger and more likely to be male. 
Patients in the two groups had similar numbers of medical encounters, though patients 
initiated on first-generation drugs had a slightly lower mean number of total drug 
prescriptions.
Medication Use
The most frequently prescribed antiepileptic drugs at treatment initiation were valproate 
(N=1158) and carabamazepine (N=724) among the first-generation drugs and oxcarbazepine 
(N=601) and topiramate (N=338) among the second-generation drugs (Table 2). The same 
relative distribution held over the course of the first year of treatment, with valproate 
(N=1439) and carbamazepine (N=867) the most frequently prescribed first-generation drugs 
and oxcarbazepine (N=780) and topiramate (N=568) the most commonly used second-
generation drugs.
Medication Retention
Measures of medication retention showed very similar utilization patterns for first- and 
second-generation drugs during the first year of treatment (Table 3). The mean duration of 
continuous treatment with an antiepileptic drug before any treatment change was 189 days 
(95% CI 185, 193) and the mean duration of continuous treatment including concurrent 
treatment with another antiepileptic drug was 203 days (95% CI 199, 207). First- and 
second-generation drugs had the same mean continuous treatment durations before any 
treatment change (189 days [95% CI 183, 194] vs. 190 days [95% CI 184, 195]) as well as 
similar mean continuous treatment when including concurrent treatment (202 days [95% CI 
197, 208] vs. 204 days [95% CI 199, 210]). The overall proportion of treatment days with 
the index drug was slightly higher for second-generation drugs (90.4% [95% CI 89.4, 91.3]) 
compared to first-generation drugs (87.4% [95% CI 86.4, 88.4]). A total of 26.4% (95% CI 
26.4, 29.0) and 29.2% (95% CI 27.3, 31.2) of patients started on a first- or second-
generation antiepileptic medication, respectively, resumed treatment with the initial drug 
after a period of discontinuation. The average period of discontinuation was 77 days (95% 
CI 73, 82) for older drugs and 79 days (95% CI 68, 76) for newer drugs.
Retention rates were similar for first- and second-generation drugs (26.1% [95% CI 24.4, 
27.9] and 26.5% [95% CI 24.6,28.4], respectively) but varied for individual medications. 
One-year survival rates for first- and second-generation agents combined and for the 
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individual drugs are shown in Figures 1 and 2. When analyzed by category, there was no 
difference in mean survival rates for first- versus second-generations drugs (p-value=0.87). 
However, within category, individual drugs did differ. For first generation drugs, phenytoin 
had a lower survival rate than any of the other drugs (carbamazepine and ethosuximide p 
<0.001, valproate p=0.007, phenobarbital p=0.017). Cabamazepine also had a longer 
survival rate than phenobarbital (p=0.003) and ethosiximide (p=0.041). Among the second-
generation drugs, oxcarbazepine had a longer survival rate than zonisamide, valproate XR, 
topiramate, gabapentin, tiagabine (p <0.001 for all) and levetiracetam (p=0.027). 
Lamotrigine had a longer survival rate than topiramate (p <0.001) and gabapentin (p=0.005). 
Carabamzepine XR had a longer retention than gabapentin (p=0.048) and topiramate 
(p=0.004). And finally, topiramate had a longer retention than tiagabine (p=0.006), but a 
shorter retention than levetiracetam (p=0.008) and zonisamide (p=0.011).
Medication changes
As shown in Table 4, overall, 72.5% (95% CI 71.2, 73.8) of patients were treated with only 
one antiepileptic drug throughout the study period, with similar rates for patients started on 
first- and second-generation antiepileptics (71.1% [95% CI 69.3, 72.9] vs 74.2% [95% CI 
72.3, 76.0]). The overall mean number of antiepileptics prescribed to each patient was 1.4 
(95% CI 1.4, 1.4) and the mean number of therapeutic changes for each patient after starting 
with the index drug was 1.8 (95% CI 1.8, 1.9). Values for these two measures were similar 
for patients started on first- and second-generation antiepileptics.
DISCUSSION
Comparing drug use in a pediatric population using observational data, we found that first- 
and second-generation antiepileptic medications had very similar utilization patterns in 
terms of medication retention and therapeutic changes. In particular, patients initiating first-
time therapy with a drug in either group had similar lengths of continuous treatment, rates of 
treatment resumption, one-year retention rates, and rates of remaining on monotherapy with 
the index drug. We demonstrates the use of pharmacy claims data for the investigation of 
drug prescription and utilization patterns and our findings provide additional information to 
complement prior studies showing that the two drug classes are similar in terms of 
effectiveness.15,25–28
This approach may be especially useful in augmenting information on drug utilization in 
pediatric populations, given the low rate of clinical trial research that has been performed in 
children compared to adults.3,5,29 A number of reports have highlighted the paucity of 
evidence derived from clinical trials in children and have also identified alarming 
deficiencies in the quality of pediatric studies.6,7,30 As a result, physicians frequently lack 
pediatric-specific data to guide clinical care around pharmacotherapy and are forced to 
extrapolate data from adult studies.31,32 Observational data on the clinical management and 
outcome of children treated with specific medications could be leveraged to fill in the gaps 
and complement data derived from controlled trials.33,34
With the widespread and continuing adoption of electronic medical records, investigators 
have access to increasing amounts of high-quality observational data on clinical care. These 
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data allow for retrospective or prospective examination of clinical data collected during 
routine clinical practice. Traditional randomized controlled studies measure the efficacy of a 
treatment using highly controlled experimental environments, volunteer patients, atypical 
physicians and healthcare settings, and protocolized care.17,35–38 The generalizability of 
their findings to clinical practice ultimately depends on how closely the trial protocols 
resemble real-world patient populations and treatment settings. Observational data, by 
contrast, are more likely to depict diverse patient populations and routine clinical care and 
are a better measure of a treatments’ effectiveness and of patients’ behaviors in standard 
practice.39,40 Other advantages of observational data include the ability to study large 
patient populations, rare diseases, multiple treatment paradigms simultaneously, and 
extended treatment periods.40,41 This can be done at fairly low cost and high speed 
compared to clinical trials.36 However, careful consideration must be given to controlling 
for confounding since the patient populations are not randomized.36,40,41 Additionally, 
observational data may not be suitable to assessing drugs newly introduced to the market as 
data on their routine clinical use will not yet be available.42
Medication retention has multiple determinants, including a patient’s willingness to continue 
a treatment, and is a composite measure of a drug’s efficacy, tolerability, safety, and patient 
preferences.43–46 It represents a measure of a drug’s overall performance in the real-world 
or, in other words, its effectiveness. As such, medication retention is considered one of the 
most relevant measures of the overall performance of an antiepileptic drug.47–49 While 
medication retention has historically been measured as the proportion of patients continuing 
therapy at a set time point following treatment initiation, examining more detailed 
components of drug retention as we did here, may provide insights into specific aspects of a 
drug’s performance. For example, we found similar proportions of patients resuming therapy 
after treatment discontinuation, indicating that the tolerability of the two drug groups are 
likely comparable. Prior studies have suggested that a drug’s tolerability may have greater 
impact in determining a drug’s long-term retention than its efficacy.43,44,50
Along the same lines, changes in therapeutic regimens may be reflective of a patient’s 
experience with a drug, including its tolerability and safety, when used in combination with 
other agents.44 Measuring changes in therapy provides additional detail to complement drug 
retention rates, focusing on a drug’s performance once its tolerability and safety in 
monotherapy has been established or identifying drug combinations that may increase a 
drug’s retention.
Measuring real-world use of medications provides the opportunity to measure the 
comparative effectiveness of specific agents within drug classes as well as the different 
treatment modalities available for a given condition. This may be particularly useful for 
conditions in which clinicians lack high-quality comparative data for the available drugs and 
other treatments.51–53 Many trials testing new drugs use placebo controls as opposed to 
active comparators and additionally may suffer from the sub-optimal choice of 
comparators.12,36 For example, a comparator drug may be unsuitable because it does not 
reflect the current standard of care for a condition or because it is administered at an 
inappropriate dose.11 Comparative metrics based on observational data allow investigators 
to evaluate a treatment of interest in relation to any number of other therapies and, 
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furthermore, incorporate patient behaviors and the conditions of administration in real-world 
practice.
The limitations of this study are those inherent to the use of retrospective claims data. There 
may be miscoding of information or missing information due to patients discontinuing 
coverage with the insurance program. However, we do not expect these factors to be related 
to the use of specific antiepileptic drugs and it is unlikely that they affect our results 
comparing patients taking different drugs. The data also did not include additional 
information on the specific types of seizures that were being treated, the rational behind 
medication choices, which may have enabled more selective inclusion of medication 
treatments for analysis. Similarly, no outcomes data is available precluding specific analysis 
of the effectiveness of the medications. Given the observational nature of the data, we 
cannot exclude potential confounding by indication, although close examination of the two 
treatment groups using the data available to us indicated that they were very similar in terms 
of demographics and disease severity as measured by medical encounters and overall drug 
use. Finally, while we employed a national dataset covering an average of 900,343 children 
annually (range 738,766 to 1,058,723), we cannot ascertain the generalizability of our 
findings to other patient populations.
CONCLUSION
Few clinical trials have compared first- and second-generation antiepileptic drugs in 
children, with the available data indicating that the two drug classes are similar in terms of 
efficacy and safety.15,25–28 Here, we compare drug utilization patterns in an observational 
pharmacy claims data set and identify similar rates of medication retention and changes. 
This approach generates information that may be useful in conjunction with traditional trial 
evidence. The methodology could readily be leveraged to other drug classes and conditions 
and may be particularly relevant to pediatric populations given the limited data frequently 
available on medication utilization in children.
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Key points
• Observational data on mediation utilization may offer the opportunity to 
measure and compare medication use to augment available trial data.
• Comparing drug utilization patterns in an observational claims data set, we 
identified similar rates of medication retention and adjustment for first- and 
second-generation drugs, consistent with prior findings.
• This approach could readily be leveraged to other drug classes and conditions to 
inform pharmacotherapeutic options and may be particularly relevant to 
pediatric populations given the limited data frequently available to guide drug 
selection in children.
Bourgeois et al. Page 12
Paediatr Drugs. Author manuscript; available in PMC 2016 October 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. Kaplan-Meier survival analysis for first- and second-generation antiepileptic drugs by 
patients during the first year of treatment
There was no difference in survival rates for first- and second-generation drugs (p-
value=0.87)
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Figure 2. Kaplan-Meier survival analysis for individual antiepileptic drugs by patients during 
the first year of therapy
Panel A depicts the five first-generation antiepileptic drugs examined. Phenytoin had 
significantly lower survival rates compared to all other drugs (carbamazepine and 
ethosuximide p <0.001, valproate p=0.007, phenobarbital p=0.017). Cabamazepine had a 
longer survival rate than phenobarbital (p =0.003) and ethosiximide (p=0.041). Panel B 
depicts the 9 second-generation drugs examined. Oxcarbazepine had a longer survival rate 
than zonisamide, valproate XR, topiramate, gabapentin, tiagabine (p <0.001 for all) and 
levetiracetam (p=0.027). Lamotrigine had a longer survival rate than topiramate (p <0.001) 
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and gabapentin (p=0.005). Carabamzepine XR had a longer retention than gabapentin 
(p=0.048) and topiramate (p=0.004). And finally, topiramate had a longer retention than 
tiagabine (p=0.006), but a shorter retention than levetiracetam (p=0.008) and zonisamide 
(p=0.011).
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Table 1
Characteristics of Patients on First- and Second-Generation Antiepileptics
Characteristic First-generation drug
(N=2527)
Second-generation drug
(N=2139)
P-value
Mean age, years 9.8 11.5 <0.001
Female, N (%) 42 51 <0.001
Mean total number of medical encountersa, N 21.3 20.7 0.34
  Mean number of outpatient visitsb 20.4 21.0 0.34
  Mean number of hospitalizations 0.3 0.3 0.56
Mean total number of drugs prescribeda,c, N 5.9 6.5 <0.001
a
During first year of therapy
b
Excludes emergency department visits
c
Includes non-antiepileptic agents
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Table 2
Utilization Rates for First- and Second-Generation Antiepileptics
Medication Year of 
regulatory
approval in the 
U.S.
Approved indicationsa Number of 
patients
initiating 
therapy, N (%)
Number 
treated 
during
N (%)
First-generation drugs 2527 (54.2) 2772
  Carbamazepine 1968 Partial seizures with complex symptomotology
Generalized tonic-clonic seizures
Mixed seizures or other partial or generalized 
seizures
724 (28.7) 867
  Ethosuximide 1960 Absence seizures 113 (4.5) 153
  Phenobarbitalc N/A Partial seizures
Generalized tonic-clonic seizures
212 (8.4) 242
  Phenytoin 1956 Partial seizures
Generalized tonic-clonic seizures
320 (12.7) 369
  Valproate 1978 Partial seizures
Absence seziures
1158 (46.8) 1439
Second-generation drugs 2139 (45.8) 2690
  Carbamazepine XR 1996 Partial seizures with complex symptomatology
Generalized tonic-clonic seizures
Mixed seizures or other partial or generalized 
seizures
163 (7.6) 235
  Gabapentin 1994 Partial seizures 240 (11.2) 329
  Lamotrigine 1994 Partial seizures
Primary generalized tonic-clonic seizures
Generalized seizures of Lennox-Gastaut syndrome
312 (14.6) 504
  Levetiracetam 1999 Partial seizures
Myoclonic seizures
162 (7.6) 324
  Oxcarbazepine 2000 Partial seizures 601 (28.1) 780
  Tiagabine 1997 Partial seizures 15 (0.7) 35
  Topiramate 1996 Generalized tonic-clonic seizures 338 (15.8) 568
  Valproate XR 2002 Partial seizures
Absence seziures
239 (11.2) 401
  Zonisamide 2000 Partial seizures 69 (3.2) 129
Abbreviations: XR, extended release
a
Indications related to epilepsy approved by the FDA in the United States as of December 31, 2006
bSum of patients for first- and second-generation drugs adds up to >100% due to some patients receiving treatment with drugs in both groups 
during the first year of treatment. Similarly, some patients were treated with more than one drug from either of the two drug groups.
c
Phenobarbital was never officially evaluated and approved by the FDA and the listed indication represents typical clinical use.
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Table 4
Measures of Therapeutic Adjustment after Treatment Initiation with First- and Second-Generation 
Antiepileptics
First Treatment
Medication
1. Proportion
monotherapy
(95% CI)
2. Proportion
polytherapy
(95% CI)
3. Number of
antiepileptic
drugs,
mean (95% CI)
4. Number of
therapeutic
adjustments,
mean (95% CI)
All antiepileptics 72.5 (71.2, 73.8) 10.4 (9.6. 11.4) 1.4 (1.4, 1.4) 1.8 (1.8, 1.9)
First-generation drugs 71.1 (69.3, 72.9) 10.8 (9.6, 12.0) 1.4 (1.4, 1.4) 1.8 (1.7, 1.9)
  Carabamazepine 71.6 (68.1, 74.8) 9.8 (7.7, 12.2) 1.4 (1.3, 1.4) 1.7 (1.6, 1.8)
  Ethosuximide 72.6 (63.4, 80.5) 8.0 (3.7, 14.6) 1.4 (1.2, 1.5) 2.0 (1.6, 2.4)
  Phenobarbital 76.9 (70.6, 82.4) 13.2 (9.0, 18.5) 1.3 (1.2, 1.4) 1.8 (1.5, 2.0)
  Phenytoin 60.3 (54.7, 65.7) 20.0 (15.8, 24.8) 1.5 (1.4, 1.6) 1.9 (1.7, 2.1)
  Valproate 72.6 (70.0, 75.2) 8.6 (7.1, 10.4) 1.4 (1.3, 1.4) 1.8 (1.7, 1.9)
Second-generation drugs 74.2 (72.3, 76.0) 10.0 (8.8, 11.4) 1.4 (1.3, 1.4) 1.8 (1.8, 1.9)
  Carbamazepine XR 69.9 (62.3, 76.9) 10.4 (6.2, 16.2) 1.4 (1.3, 1.5) 1.9 (1.6, 2.2)
  Gabapentin 71.7 (65.5, 77.3) 8.3 (5.2, 12.6) 1.4 (1.3, 1.5) 1.9 (1.7, 2.1)
  Lamotrigine 79.2 (74.2, 83.5) 11.9 (8.5, 16.0) 1.3 (1.2, 1.4) 1.8 (1.6, 2.0)
  Levetiracetam 72.8 (65.3, 79.5) 14.8 (9.7, 21.2) 1.4 (1.2, 1.4) 1.8 (1.5, 2.1)
  Oxcarbazepine 77.5 (74.0, 80.8) 8.5 (6.4, 11.0) 1.3 (1.3, 1.4) 1.7 (1.5, 1.8)
  Tiagabine 73.3 (44.9, 92.2) 6.7 (0.2, 32.0) 1.4 (0.9, 1.9) 2.2 (1.2, 3.2)
  Topiramate 75.4 (70.5, 79.9) 7.7 (5.1, 11.1) 1.3 (1.3, 1.4) 2.1 (1.9, 2.3)
  Valproate XR 65.7 (59.3, 71.7) 13.8 (9.7, 18.8) 1.5 (1.4, 1.6) 2.0 (1.8, 2.2)
  Zonisamide 68.1 (55.8, 78.8) 8.7 (3.3, 18.0) 1.4 (1.2, 1.5) 1.6 (1.2, 1.9)
Abbreviations: XR, extended release
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Appendix Table 2
Sensitivity Analysis for Measures of Therapeutic Adjustment after Treatment Initiation with First- and 
Second-Generation Antiepileptics
First Treatment
Medication
1. Proportion
monotherapy
(95% CI)
2. Proportion
polytherapy
(95% CI)
3. Number of
antiepileptic
drugs,
mean (95% CI)
4. Number of
therapeutic
adjustments,
mean (95% CI)
All antiepileptics 69.8 (68.8, 71.1) 9.2 (8.4, 10.0) 1.4 (1.4, 1.4) 1.8 (1.8, 1.9)
  First-generation drugs 68.6 (66.8, 70.2) 9.2 (8.2, 10.3) 1.4 (1.4, 1.4) 1.8 (1.7, 1.9)
  Second-generation drugs 71.5 (69.6, 73.4) 9.1 (7.9, 10.3) 1.4 (1.4, 1.4) 1.8 (1.8, 1.9)
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